{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:25:26Z","timestamp":1783455926216,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,24]]},"DOI":"10.7759\/cureus.29531","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T14:48:56Z","timestamp":1664030936000},"source":"Crossref","is-referenced-by-count":3,"title":["Role of Prophylactic Steroids in Differentiation Syndrome"],"prefix":"10.7759","author":[{"given":"Jakia","family":"Sultana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Mustarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proma","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Y","family":"Mamoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009657","article-title":"Case report: purulent transformation of granulocytic sarcoma: an unusual pattern of differentiation in acute promyelocytic leukemia","volume":"97","author":"Collinge E","year":"2018","unstructured":"Collinge E, Tigaud I, Balme B, et al.. Case report: purulent transformation of granulocytic sarcoma: an unusual pattern of differentiation in acute promyelocytic leukemia. Medicine (Baltimore). 2018, 97:e9657. 10.1097\/MD.0000000000009657","journal-title":"Medicine (Baltimore)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet SL","year":"1998","unstructured":"Soignet SL, Maslak P, Wang ZG, et al.. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339:1341-8. 10.1056\/NEJM199811053391901","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.10.5302","article-title":"Acute leukemia with promyelocytic features in PML\/RAR\u03b1 transgenic mice","volume":"94","author":"He LZ","year":"1997","unstructured":"He LZ, Tribioli C, Rivi R, et al.. Acute leukemia with promyelocytic features in PML\/RAR\u03b1 transgenic mice. Proc Natl Acad Sci U S A. 1997, 94:5302-7. 10.1073\/pnas.94.10.5302","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02790-w","article-title":"Multidisciplinary corroboration in differentiation syndrome: a case report","volume":"15","author":"Sarkar S","year":"2021","unstructured":"Sarkar S, Ghosh P, Gehani A, Ghara N, Bhattacharyya P. Multidisciplinary corroboration in differentiation syndrome: a case report. J Med Case Rep. 2021, 15:226. 10.1186\/s13256-021-02790-w","journal-title":"J Med Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz MA","year":"2014","unstructured":"Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014, 123:2777-82. 10.1182\/blood-2013-10-512640","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl M","year":"2019","unstructured":"Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019, 187:157-62. 10.1111\/bjh.16151","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12042","article-title":"Differentiation syndrome, a side effect from the therapy of acute promyelocytic leukemia","volume":"12","author":"Reyhanoglu G","year":"2020","unstructured":"Reyhanoglu G, Hughes B, King KE, Cambridge R. Differentiation syndrome, a side effect from the therapy of acute promyelocytic leukemia. Cureus. 2020, 12:e12042. 10.7759\/cureus.12042","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4081\/hr.2014.5654","article-title":"Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis","volume":"6","author":"Cabral R","year":"2014","unstructured":"Cabral R, Caballero JC, Alonso S, et al.. Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. Hematol Rep. 2014, 6:5654. 10.4081\/hr.2014.5654","journal-title":"Hematol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2018.9.2.4","article-title":"Acute promyelocytic leukemia: a summary","volume":"9","author":"Ryan MM","year":"2018","unstructured":"Ryan MM. Acute promyelocytic leukemia: a summary. J Adv Pract Oncol. 2018, 9:178-87. 10.6004\/jadpro.2018.9.2.4","journal-title":"J Adv Pract Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos P","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E, et al.. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009, 113:775-83. 10.1182\/blood-2008-07-168617","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369:111-21. 10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland HJ","year":"2012","unstructured":"Iland HJ, Bradstock K, Supple SG, et al.. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012, 120:1570-80. 10.1182\/blood-2012-02-410746","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276196","article-title":"Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group","volume":"116","author":"Lo-Coco F","year":"2010","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood. 2010, 116:3171-9. 10.1182\/blood-2010-03-276196","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz MA","year":"2004","unstructured":"Sanz MA, Mart\u00edn G, Gonz\u00e1lez M, et al.. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004, 103:1237-43. 10.1182\/blood-2003-07-2462","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi F","year":"2009","unstructured":"Ravandi F, Estey E, Jones D, et al.. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009, 27:504-10. 10.1200\/JCO.2008.18.6130","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome","volume":"115","author":"Sanz MA","year":"2010","unstructured":"Sanz MA, Montesinos P, Ray\u00f3n C, et al.. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010, 115:5137-46. 10.1182\/blood-2010-01-266007","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-449918","article-title":"Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL","volume":"121","author":"Rego EM","year":"2013","unstructured":"Rego EM, Kim HT, Ruiz-Arg\u00fcelles GJ, et al.. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013, 121:1935-43. 10.1182\/blood-2012-08-449918","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211399163","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia","volume":"18","author":"Rogers JE","year":"2012","unstructured":"Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. J Oncol Pharm Pract. 2012, 18:109-14. 10.1177\/1078155211399163","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115503-role-of-prophylactic-steroids-in-differentiation-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:01Z","timestamp":1707508141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115503-role-of-prophylactic-steroids-in-differentiation-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.29531","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,24]]}}}